1 Momentum Stock Worth Investigating and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. All that said, here is one stock we think lives up to the hype and two not so much.
Two Stocks to Sell:
Allient (ALNT)
One-Month Return: +23.8%
Founded in 1962, Allient (NASDAQ:ALNT) develops and manufactures precision and specialty-controlled motion components and systems.
Why Are We Hesitant About ALNT?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Underwhelming 7.8% return on capital reflects management’s difficulties in finding profitable growth opportunities
At $118.38 per share, Allient trades at 37.8x forward P/E. To fully understand why you should be careful with ALNT, check out our full research report (it’s free).
Simmons First National (SFNC)
One-Month Return: -1.4%
With roots dating back to 1903 and a presence across Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas, Simmons First National (NASDAQ:SFNC) is a regional bank holding company that provides banking and financial services to individuals and businesses.
Why Do We Pass on SFNC?
- Net interest income trends were unexciting over the last five years as its 5.4% annual growth was below the typical banking firm
- Overall productivity is expected to decrease over the next year as Wall Street thinks its efficiency ratio will degrade by 17.6 percentage points
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 4.5% annually while its revenue grew
Simmons First National is trading at $22.90 per share, or 0.9x forward P/B. Dive into our free research report to see why there are better opportunities than SFNC.
One Stock to Watch:
Medpace (MEDP)
One-Month Return: +1%
Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ:MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.
Why Is MEDP on Our Radar?
- Average organic revenue growth of 17.2% over the past two years demonstrates its ability to expand independently without relying on acquisitions
- Performance over the past five years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue
- Free cash flow margin jumped by 6 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
Medpace’s stock price of $596.56 implies a valuation ratio of 32.4x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.